Key Highlights

  • Revenue for the half-year ended 30 June 2026 was AUD 1.43mn.
  • A multi-year China collaboration has a value above RMB 12mn, approximately AUD 2.5mn.
  • Osteopore expanded distribution into Latin America, Malaysia and the Middle East.
  • The company’s cleft lip trial completed patient recruitment and its jaw reconstruction trial commenced.

Osteopore (ASX: OSP) is moving through a period where commercial expansion and clinical development are advancing together. The company reported AUD 1.43mn in half-year Revenue to 30 June 2026, while new distribution arrangements, product collaborations and clinical milestones widened the potential reach of its 3D-printed bone-regeneration technology.

Revenue Holds Broadly Steady in Underlying Currencies

Revenue declined 8% in Australian-dollar terms to AUD 1.43mn. Osteopore said revenue was broadly consistent on a constant-currency basis, with the reported decline largely reflecting currency translation. Growth in the Philippines, Vietnam, Japan, the United States and Singapore partly offset weaker sales in several other markets.

China Collaboration Opens a Larger Commercial Door

Osteopore entered a multi-year exclusive collaboration with Majeton to commercialise its dental, orthodontic and maxillofacial products in China, Hong Kong and Macau. The arrangement is valued above RMB 12mn, approximately AUD 2.5mn, and the first milestone payment of RMB 2.5mn, about AUD 520,000, was received in March 2026.

Distribution Footprint Continues to Expand

During the period, Osteopore expanded its orthopaedic Business into Hong Kong and signed a Latin American distribution agreement covering a 20-country region. It also secured Malaysian regulatory market access for its orthopaedic portfolio and entered a three-year Middle East distribution agreement covering Saudi Arabia, the UAE, Oman, Qatar and Bahrain.

Clinical Programs Add Another Layer

Osteopore’s cleft lip augmentation clinical trial at Queensland Children’s Hospital completed patient recruitment, with treatment of the first two patients completed. Its jaw reconstruction clinical trial at Princess Alexandra Hospital also commenced. These programs sit alongside the company’s commercialisation activities across its approved product portfolio.